Cat. #151046
Anti-HLAD/DR, DQ [35]
Cat. #: 151046
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Human Leukocyte Antigen (HLA) D/DR, DQ (MHC Class II)
Class: Monoclonal
Application: FACS ; IHC ; IP
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Nancy Hogg
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-HLAD/DR, DQ [35]
- Clone: 35
- Tool type ecom: Antibodies
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IP
- Description: Human Leukocyte Antigens (HLA) are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). Clone 35 can be used for HLA typing, cytotoxic, binding and biochemical assays.
- Immunogen: Hairy gene product
- Isotype: IgG3
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Human Leukocyte Antigen (HLA) D/DR, DQ (MHC Class II)
- Target background: Human Leukocyte Antigens (HLA) are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). Clone 35 can be used for HLA typing, cytotoxic, binding and biochemical assays.
Applications
- Application: FACS ; IHC ; IP
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Allen et al. 1987. Cancer Res. 47(11):2919-23. PMID: 3105871.
- Association of colorectal tumor epithelium expressing HLA-D/DR with CD8-positive T-cells and mononuclear phagocytes.
